IRS
NKTR icon

Invictus RG (Singapore)’s Nektar Therapeutics NKTR Stock Holding History

Invictus RG (Singapore)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-231
Closed -$44K – 707
2014
Q2 		$44K Buy
231
+129
+126% +$22.8K 0.05% 413
2014
Q1 		$18K Buy
+102
New +$20.2K 0.02% 508

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invictus RG (Singapore)'s NKTR Position: Q3 2014 in Review

Invictus RG (Singapore) sold out of Nektar Therapeutics (NKTR) in Q3 2014, closing a stake of 231 shares — an estimated $44K sold.

Invictus RG (Singapore) first reported a position in NKTR in Q1 2014 and held it in 2 quarters. The position peaked at $44K in Q2 2014. 145 funds tracked by Wall St. Rank hold NKTR as of Q3 2014.

  • Invictus RG (Singapore) reported no remaining Nektar Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Invictus RG (Singapore) sold 231 Nektar Therapeutics shares in Q3 2014, an estimated $44K.
  • Invictus RG (Singapore) first reported a position in Nektar Therapeutics in Q1 2014 and held it in 2 quarters.
  • Invictus RG (Singapore)'s Nektar Therapeutics position peaked at $44K in Q2 2014.
  • 145 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2014.

Based on Invictus RG (Singapore)'s 13F filing for Q3 2014, filed 14 Nov 2014.